SCHEMBL322859

SCHEMBL322859

Oc1cc(Cl)c(-c2cccc(F)c2)cc1-c1ccnnc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
WNT3A P56704 6/20 0.41
BRAF P15056 1/20 0.40
ESR2 Q92731 1/20 0.38
IDO1 P14902 1/20 0.37
FYN P06241 1/20 0.37
MAPT P10636 2/20 0.36
ALOX15 P16050 2/20 0.36
NFKB1 P19838 2/20 0.36
NFKB2 Q00653 2/20 0.36
RELA Q04206 2/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
LMNA P02545 1/20 0.36
TP53 P04637 1/20 0.36
ALOX12 P18054 1/20 0.36
MAPK1 P28482 1/20 0.36
GPR35 Q9HC97 1/20 0.36
DPP4 P27487 1/20 0.36
CDC7 O00311 1/20 0.35
ROCK2 O75116 1/20 0.35
MAP4K4 O95819 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL322167 0.94 WNT3A (0.41) WNT3ABRAFESR2FYNMAPT
SCHEMBL322648 0.84 RPS6KA3 (0.47) BRAFIDO1SMN1; SMN2TP53NPC1
SCHEMBL323025 0.83 RORB (0.44) BRAFIDO1MAPTALOX15ALOX12
SCHEMBL323651 0.79 BRAF (0.41) BRAFSMN1; SMN2SCN9A
SCHEMBL321988 0.78 RPS6KA3 (0.47) BRAFSMN1; SMN2TP53GSK3BCLK4
SCHEMBL322242 0.75 ESR2 (0.43) ESR2FYNMAPTALOX15NFKB1
SCHEMBL322244 0.72 ESR2 (0.43) ESR2FYNMAPTALOX15NFKB1
SCHEMBL321954 0.71 PIM1 (0.50) BRAFIDO1MAPTALOX15SMN1; SMN2
SCHEMBL18617426 0.70 FASN (0.45) ESR2GPR35MAP4K4NPSR1
SCHEMBL29587732 0.70 FASN (0.45) ESR2GPR35MAP4K4NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2590951-B1 BENZENESULFONAMIDES USEFUL AS SODIUM CHANNEL INHIBITORS PFIZER LTD (GB) 2015-01-07 EP disclosed
EP-2590951-B1 BENZENESULFONAMIDES USEFUL AS SODIUM CHANNEL INHIBITORS PFIZER LTD (GB) 2015-01-07 EP disclosed
US-8772293-B2 Chemical compounds PFIZER LIMITED (GB) 2014-07-08 US disclosed
US-8772293-B2 Chemical compounds PFIZER LIMITED (GB) 2014-07-08 US disclosed
US-8772293-B2 Chemical compounds PFIZER LIMITED (GB) 2014-07-08 US disclosed
EP-2590951-A1 BENZENESULFONAMIDES USEFUL AS SODIUM CHANNEL INHIBITORS Pfizer Limited (GB) 2013-05-15 EP disclosed
WO-2012004743-A1 BENZENESULFONAMIDES USEFUL AS SODIUM CHANNEL INHIBITORS PFIZER LIMITED (GB) 2012-01-12 WO disclosed
WO-2012004743-A1 BENZENESULFONAMIDES USEFUL AS SODIUM CHANNEL INHIBITORS PFIZER LIMITED (GB) 2012-01-12 WO disclosed
US-20120010182-A1 Chemical Compounds ICAGEN INC. (US) 2012-01-12 US disclosed
US-20120010182-A1 Chemical Compounds ICAGEN INC. (US) 2012-01-12 US disclosed
US-20120010182-A1 Chemical Compounds ICAGEN INC. (US) 2012-01-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120010182-A1 Chemical Compounds SCN1A, SCN1B, CACNA1E WNT3A 1858/4885BRAF 166/4885ESR2 2584/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.